Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301124 | 1.00 | REN (0.44) | RENCYP3A4PDE4B | |
| SCHEMBL4305357 | 1.00 | REN (0.44) | RENCYP3A4PDE4B | |
| SCHEMBL3913702 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL3912243 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL3991486 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL3991494 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL4305822 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL3912240 | 0.90 | PDE4B (0.40) | RENCYP3A4PDE4B | |
| SCHEMBL3913872 | 0.88 | REN (0.44) | RENCYP3A4 | |
| SCHEMBL4310358 | 0.88 | REN (0.44) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270417-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270417-A1 | Organic Compounds | REN, ACE, OTC | REN 1/4885CYP3A4 173/4885PDE4B 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.